Home Ingredients NūGensia™ (Akkermansia muciniphila Postbiotic)
Metabolic HealthGut HealthWeight Management

NūGensia™ (Akkermansia muciniphila Postbiotic)

Akkermansia muciniphila
Evidence Level
Limited
2 Clinical Trials
3 Documented Benefits
2/5 Evidence Score

NūGensia is a branded Akkermansia muciniphila (strain VHAKM) postbiotic from Vidya Herbs, supplied as starch-shell encapsulated non-living cells dosed at about 10 billion cells per day and marketed for blood sugar, weight and metabolic support. Akkermansia muciniphila has human trial evidence, including a proof-of-concept randomized trial in overweight adults and a controlled weight-maintenance trial, but those trials used a different Akkermansia strain rather than VHAKM. NuGensia's own trial of the VHAKM strain is not published in a PubMed-indexed journal, so its results cannot be independently checked. See the generic Akkermansia muciniphila entry.

Studied Dose Manufacturer trial: ~10 billion CFU/day for 60 days. The landmark Akkermansia RCT used ~10 billion cells/day (live or pasteurized).
Active Compound Akkermansia muciniphila (strain VHAKM), starch-shell encapsulated, ~10 billion CFU/day. NūGensia™ is manufactured by Vidya Herbs.

Benefits

Improved glucose and metabolic markers

Pasteurized Akkermansia muciniphila improved insulin sensitivity and several metabolic markers versus placebo in a controlled human trial, though that trial used a different Akkermansia strain. The maker reports metabolic improvements in its own trial of this branded strain, but that trial is not published in a searchable journal, so its results cannot be independently checked.

Supported by Trial 1, Trial 2

Weight and waist support

In a controlled human trial, pasteurized Akkermansia muciniphila led to less weight regain after dieting and greater net weight loss than placebo. That trial used a different Akkermansia strain, so this effect has not been shown for the specific VHAKM strain in NuGensia.

Supported by Trial 2, Trial 1

Gut-barrier support

Akkermansia is a mucin-associated commensal that strengthens the gut barrier, a mechanism linking it to metabolic health.

Supported by Trial 1, Trial 2

Mechanism of action

1

Gut-barrier and mucin layer support

Akkermansia muciniphila lives in and reinforces the intestinal mucus layer, reducing 'leaky gut' and the low-grade inflammation that drives metabolic dysfunction.

2

Metabolic endotoxemia reduction

By tightening the gut barrier, Akkermansia lowers circulating bacterial endotoxin, improving insulin sensitivity and metabolic markers.

Clinical trials

1
Akkermansia muciniphila and Metabolic Markers: Proof-of-Concept RCT
PubMed

Randomized, double-blind, placebo-controlled pilot in overweight or obese insulin-resistant adults (40 enrolled, 32 completed); daily live or pasteurized Akkermansia muciniphila for three months. Used a different Akkermansia strain, not the NuGensia VHAKM strain. (Depommier et al. 2019, Nature Medicine)

Overweight or obese insulin-resistant adults (40 enrolled, 32 completed).

Compared with placebo, pasteurized Akkermansia muciniphila improved insulin sensitivity (about 29 percent, p=0.002) and lowered insulinemia and total cholesterol. Body weight was only slightly lower, and that change was not statistically significant (p=0.091). Several authors co-founded an Akkermansia company and hold related patents.

2
Pasteurized Akkermansia muciniphila and Weight Regain After Dieting: RCT
PubMed

Randomized controlled trial in 90 adults with overweight or obesity: an 8-week low-energy diet, then 24 weeks of daily pasteurized Akkermansia muciniphila or placebo. Used a different Akkermansia strain, not the NuGensia VHAKM strain. (Mount et al. 2026, Nature Medicine)

90 adults with overweight or obesity.

Weight regained during the maintenance period was lower with pasteurized Akkermansia than placebo (1.2 versus 3.2 kg, p=0.012), and net weight loss from baseline was greater (by about 3.1 kg, p=0.009). Several authors are employees or advisors of the company that makes the strain and hold a related patent.

Side effects and drug interactions

Common Potential side effects

Generally well tolerated; Akkermansia is a normal human gut commensal.
Mild, transient bloating or changes in bowel habit possible when starting.
Immunocompromised individuals should use live/postbiotic bacteria under clinician guidance.
Long-term data are still accumulating for this relatively new probiotic.

Important Drug interactions

No well-documented drug interactions.
Antidiabetic medications: monitor glucose, as additive effects are plausible given the metabolic action.

Featured in these supplement guides

Blood Sugar Control→

More Metabolic Health Ingredients

Metabolic Health
Psyllium Husk (Plantago ovata)
Psyllium husk is the seed coat of Plantago ovata, a gel-forming soluble fiber sold as a bu…
Metabolic Health
Thiamine
Thiamine, also known as vitamin B1, is a water-soluble vitamin essential for converting ca…
Metabolic Health
Magnesium
Magnesium is an essential mineral and a cofactor in more than 300 enzyme systems, includin…
Metabolic Health
Ginger (Zingiber officinale)
Ginger is a culinary spice with a long history of traditional use. Its pungent compounds a…

Explore Other Ingredients

Immune Support
Probiotics (Multi-strain Blends)
Multi-strain probiotic blends combine live microbes, usually from Lactobacillus and Bifido…
Metabolic Health
Inulin
Inulin is a soluble prebiotic fiber found naturally in chicory root, agave, and many veget…
Muscle & Recovery
L-Glutamine
L-glutamine is the most abundant amino acid in the body, and cells of the intestinal linin…

Frequently asked questions about NūGensia™ (Akkermansia muciniphila Postbiotic)

What is NūGensia?

NuGensia is Vidya Herbs' branded Akkermansia muciniphila postbiotic, encapsulated for stability and dosed around 10 billion cells per day for blood sugar, weight and metabolic support.

Is Akkermansia actually proven?

Akkermansia muciniphila has human trial evidence, including a proof-of-concept randomized trial and a controlled weight-maintenance trial in adults with overweight or obesity. Those trials used a different Akkermansia strain, not VHAKM, and NuGensia's own VHAKM trial is manufacturer-run and not published in a PubMed-indexed journal.

What is NūGensia used for?

NūGensia is researched primarily for Metabolic Health, Gut Health, and Weight Management. Pasteurized Akkermansia muciniphila improved insulin sensitivity and several metabolic markers versus placebo in a controlled human trial, though that trial used a different Akkermansia strain.

What is the recommended dosage of NūGensia?

The clinically studied dose is Manufacturer trial: ~10 billion CFU/day for 60 days. The landmark Akkermansia RCT used ~10 billion cells/day (live or pasteurized). Always follow the product label and check with a healthcare provider for personal advice.

Is NūGensia safe, and does it have side effects?

Side effects and cautions reported for NūGensia include: Generally well tolerated; Akkermansia is a normal human gut commensal. Mild, transient bloating or changes in bowel habit possible when starting. It may also interact with some medications. NūGensia is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does NūGensia interact with any medications?

Possible interactions include: No well-documented drug interactions. Antidiabetic medications: monitor glucose, as additive effects are plausible given the metabolic action. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for NūGensia?

NutraSmarts rates the evidence for NūGensia as Limited (2 out of 5). It is backed by 2 study summaries and 2 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(2 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Mount S, Canfora EE, Jocken JW, Umanets A, Hul G, Coenjaerds M, Aldaz Laquidain P, Adriaens ME, Holst JJ, Jardon KM, Segers A, Suenaert P, de Vos WM, Blaak EE. Pasteurized Akkermansia muciniphila Muc(T) for weight loss maintenance in people with overweight and obesity: a controlled randomized trial. Nature Medicine. 2026;32(6):2107-2116. doi: 10.1038/s41591-026-04394-7.PubMedUsed to support: A randomized controlled trial in 90 adults found that pasteurized Akkermansia muciniphila lowered weight regain after a low-energy diet versus placebo (1.2 versus 3.2 kg, p=0.012) and produced greater net weight loss (p=0.009). It used a different Akkermansia strain, not the VHAKM strain in NuGensia. Several authors work for or advise the company that makes the strain.
  2. Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G, Raes J, Maiter D, Delzenne NM, de Barsy M, Loumaye A, Hermans MP, Thissen JP, de Vos WM, Cani PD. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine. 2019;25(7):1096-1103. doi: 10.1038/s41591-019-0495-2.PubMedUsed to support: A proof-of-concept randomized pilot (40 enrolled, 32 completed) found that pasteurized Akkermansia muciniphila improved insulin sensitivity and lowered total cholesterol versus placebo, with no statistically significant change in body weight. It used a different Akkermansia strain, not the VHAKM strain in NuGensia. Authors include co-founders of an Akkermansia company who hold related patents.